<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394511</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02483</org_study_id>
    <secondary_id>SWOG-8794</secondary_id>
    <secondary_id>CAN-NCIC-PR2</secondary_id>
    <secondary_id>CLB-9493</secondary_id>
    <secondary_id>EST-9887</secondary_id>
    <secondary_id>NCCTG-895251</secondary_id>
    <secondary_id>RTOG-9019</secondary_id>
    <secondary_id>INT-0086</secondary_id>
    <secondary_id>CDR0000075112</secondary_id>
    <nct_id>NCT00394511</nct_id>
  </id_info>
  <brief_title>Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer</brief_title>
  <official_title>Phase III Randomized Evaluation of Adjuvant Radiotherapy vs No Adjuvant Therapy Following Radical Prostatectomy and Pelvic Lymphadenectomy in Surgical Stage C Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare treatment with or without adjuvant radiation therapy in&#xD;
      men with stage III prostate cancer who have had radical prostatectomy and lymphadenectomy&#xD;
      recently. Radiation therapy uses high-energy x-rays to damage tumor cells and may be an&#xD;
      effective treatment for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare disease-free survival rates of patients randomly assigned to adjuvant&#xD;
      external-beam radiotherapy vs. no adjuvant therapy following radical prostatectomy and pelvic&#xD;
      lymphadenectomy for surgical Stage C (T3 N0 M0) adenocarcinoma of the prostate.&#xD;
&#xD;
      II. Determine the qualitative and quantitative toxicities associated with this adjuvant&#xD;
      therapy.&#xD;
&#xD;
      OUTLINE: Randomized study. Randomization takes place when the patient is physically able to&#xD;
      begin treatment, any time within 16 weeks after surgery.&#xD;
&#xD;
      Arm I: Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with&#xD;
      effective photon energies of greater than 4 MV.&#xD;
&#xD;
      Arm II: No further treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1988</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Pathologically documented Stage C (T3 N0 M0) adenocarcinoma of the prostate following&#xD;
             radical prostatectomy and pelvic lymphadenectomy for clinical Stage A/B disease&#xD;
&#xD;
          -  Ineligible for SWOG protocols of higher priority&#xD;
&#xD;
          -  At least 1 of the following on pathologic examination:&#xD;
&#xD;
               -  Presence of cancer in the seminal vesicles&#xD;
&#xD;
               -  Evidence of cancer at the inked surgical margin of the prostate&#xD;
&#xD;
               -  Extension of tumor beyond the prostatic capsule&#xD;
&#xD;
          -  Negative preoperative metastatic survey within 6 months prior to registration,&#xD;
             including the following:&#xD;
&#xD;
               -  Normal bone scan&#xD;
&#xD;
               -  No palpable evidence of extraprostatic tumor extension&#xD;
&#xD;
          -  Bilateral lymph node dissection histologically negative for cancer&#xD;
&#xD;
          -  Nodal sampling not required with the following stage/biopsy specimen Gleason&#xD;
             score/preoperative PSA:&#xD;
&#xD;
               -  Stage T1a/2-6/&lt;10 ng/ml&#xD;
&#xD;
               -  Stage T1b-c/2-5/&lt;10 ng/ml&#xD;
&#xD;
               -  Stage T2a/2-6/&lt;10 ng/ml&#xD;
&#xD;
               -  Stage T2b/2-6/&lt;6 ng/ml&#xD;
&#xD;
               -  Stage T2c/2-6/&lt;4 ng/ml&#xD;
&#xD;
          -  Free from the following postoperative complications:&#xD;
&#xD;
               -  Total urinary incontinence&#xD;
&#xD;
               -  Intraoperative rectal injury&#xD;
&#xD;
               -  persistent urinary extravasation&#xD;
&#xD;
               -  Pelvic infection&#xD;
&#xD;
          -  Concurrent registration on protocol SWOG-9205 (serum repository protocol) optional&#xD;
&#xD;
          -  Concurrent registration on protocol SWOG-8994 (quality-of-life study) required of&#xD;
             English-speaking and Spanish-speaking patients enrolled by SWOG&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: Any age&#xD;
&#xD;
          -  Performance status: SWOG 0-2&#xD;
&#xD;
          -  Life expectancy: At least 2 years&#xD;
&#xD;
          -  Hematopoietic:&#xD;
&#xD;
               -  WBC at least institutional LLN&#xD;
&#xD;
               -  Platelets at least institutional LLN&#xD;
&#xD;
          -  Hepatic: SGOT no more than 2 x ULN&#xD;
&#xD;
          -  Other: No second malignancy within 5 years except adequately treated nonmelanomatous&#xD;
             skin cancer&#xD;
&#xD;
        --Prior Concurrent Therapy--&#xD;
&#xD;
          -  Chemotherapy: No prior chemotherapy for prostate cancer&#xD;
&#xD;
          -  Endocrine therapy: No more than 3 months of hormonal therapy prior to prostatectomy&#xD;
             allowed&#xD;
&#xD;
          -  Radiotherapy: No prior radiotherapy for prostate cancer&#xD;
&#xD;
          -  Surgery: Radical prostatectomy and pelvic lymphadenectomy within 16 weeks prior to&#xD;
             registration required&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <reference>
    <citation>Thompson IM, Paradelo JC, Crawford ED, Coltman CA, Blumenstein B. An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing. Urology. 1994 Dec;44(6):804-11. Review.</citation>
    <PMID>7985307</PMID>
  </reference>
  <results_reference>
    <citation>Swanson GP, Thompson IM, Tangem C, et al.: Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794). [Abstract] Int J Radiat Oncol Biol Phys 63 (Suppl 1): A-1, S1, 2005.</citation>
  </results_reference>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

